NAD+, NMN, and NR are three of the most-marketed compounds in the longevity space. They are also commonly conflated. They are different molecules with different routes of administration, different bioavailability profiles, different regulatory statuses, and different evidence bases.
This post is the practical comparison framework: what each compound actually is, what the evidence shows, and what clinically grounded use looks like in 2026.
What NAD+ does in the body
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, central to:
- Mitochondrial energy production. NAD+ shuttles electrons through the electron transport chain to produce ATP.
- DNA repair. NAD+ is required for PARP enzymes that repair DNA damage.
- Sirtuin signaling. NAD+ activates the sirtuin pathway, which regulates gene expression involved in metabolism, inflammation, and aging.
- Cellular redox balance. NAD+ moves between oxidized (NAD+) and reduced (NADH) forms across many metabolic reactions.
Tissue NAD+ levels decline with age. The decline correlates with metabolic dysfunction, reduced mitochondrial function, and various aging-related changes. The hypothesis behind raising NAD+ levels: if low NAD+ is part of why aging happens, raising NAD+ might slow some aging processes. This is plausible mechanistically. Whether it produces clinical benefit at the magnitude marketing suggests is much less clear.
For how TelePep offers prescribed NAD+, see the NAD+ program page.
The four main approaches
1. Direct NAD+ injection (subcutaneous or IV)
What it is: Pharmaceutical-grade NAD+ administered by injection (subcutaneous self-administration at home, or IV in a clinic setting).
Route: Subcutaneous most common for self-administered prescribed protocols; IV for clinic-administered higher doses.
Bioavailability: Not dependent on gastric absorption (a route difference; there is no head-to-head outcome data against oral precursors).
Dose: Set by the prescribing clinician and printed on the pharmacy label; not a patient decision.
Evidence: Research is ongoing; clinical-outcome evidence is mixed depending on the population studied, and benefits are not established.
Regulatory: NAD+ has a USP monograph and is legitimately compounded by 503A pharmacies. Prescribed and dispensed by licensed clinician + licensed pharmacy.
Cost: Through direct-pay telehealth, $99-$300/month for typical home-injection protocols. Clinic IV sessions range $300-$800 per session.
Practical fit: The prescribed route, with clinical oversight. Whether a larger NAD+ elevation translates into any benefit has not been established. Covered in detail in NAD+ at-home self-administered protocols.
2. Oral NMN (nicotinamide mononucleotide)
What it is: A direct precursor to NAD+, one metabolic step away from NAD+ itself.
Route: Oral capsule or sublingual.
Bioavailability: Limited. NMN appears to be partially broken down to nicotinamide in the gut before absorption, then converted back to NMN in tissues. The net NAD+ elevation from oral NMN is measurable but modest.
Dose: Varies by product; follow the product label.
Evidence: Small human studies show measurable but modest increases in blood NAD+ levels. Functional endpoint studies have produced mixed results: some signals on insulin sensitivity, exercise capacity, sleep quality; many null findings.
Regulatory status (2022-2026): Complicated. NMN was sold widely as a dietary supplement until November 2022, when FDA notified manufacturers that NMN had been the subject of an investigational new drug (IND) application and was therefore reclassified as a drug, not a supplement. The status remains contested as of 2026: some manufacturers continue to sell NMN as a supplement; FDA enforcement has been inconsistent. The honest read: NMN is in regulatory limbo. It is widely available but not on solid legal ground as a supplement, and not approved as a drug.
Cost: $30-$80/month for typical supplement doses.
Practical fit: For consumers who want oral convenience and accept the bioavailability and regulatory uncertainty.
3. Oral NR (nicotinamide riboside)
What it is: Another NAD+ precursor, two metabolic steps from NAD+.
Route: Oral capsule, most commonly sold as the chloride salt (nicotinamide riboside chloride, branded "Niagen" by ChromaDex).
Bioavailability: Better than NMN through the oral route: NR appears to survive gastric breakdown more reliably and convert to NAD+ in tissues.
Dose: Varies by product; follow the product label.
Evidence: Multiple small-to-medium human studies show measurable NAD+ elevation. Clinical-outcome studies have been mixed: modest signals on some markers (insulin sensitivity, blood pressure) and null findings on others. No dramatic longevity-marketing effects established.
Regulatory status: Sold as a dietary supplement (legal, regulated by DSHEA rules for supplements rather than drug rules). The branded Niagen formulation is the most-studied.
Cost: $30-$80/month for typical supplement doses.
Practical fit: The most-established consumer NAD+ precursor option. Reasonable choice for patients wanting an oral approach with the most-studied evidence base among oral options.
4. Niacin and niacinamide (broader B3 family)
What it is: Niacin (nicotinic acid) and niacinamide (nicotinamide) are simpler B-vitamin forms that also serve as NAD+ precursors.
Route: Oral.
Bioavailability: Good but the conversion path is longer (more metabolic steps to reach NAD+).
Evidence: Strong evidence base for traditional uses (lipid management for niacin; broader B-vitamin nutrition for both). Specific NAD+-elevation evidence is more limited; the conversion is slower and partial.
Cost: Very low. $5-$15/month for typical doses.
Practical fit: Adequate for general B-vitamin sufficiency; not the primary NAD+-elevation strategy in modern protocols.
Side-by-side comparison
| Property | Injectable NAD+ | Oral NMN | Oral NR | Niacinamide |
|---|---|---|---|---|
| Route | Injection (no gastric absorption) | Oral | Oral | Oral |
| Regulatory status | USP monograph; 503A compoundable | Contested (supplement vs drug) | Supplement (DSHEA) | Supplement |
| Cost / month | $99-300 (telehealth) | $30-80 | $30-80 | $5-15 |
| Clinical oversight | Yes, prescribed | No | No | No |
| Convenience | Self-injection | Oral capsule | Oral capsule | Oral capsule |
The clinical question
The honest framing: NAD+ supplementation is one of the more promising and one of the more overmarketed areas of longevity intervention.
The mechanism is real. NAD+ levels do decline with age. NAD+ is centrally involved in mitochondrial function, DNA repair, and sirtuin signaling.
The clinical translation is uneven. The studies that have looked at functional endpoints (exercise capacity, cognitive function, insulin sensitivity, sleep quality) have produced modest, mixed, and sometimes null results. The dramatic longevity-marketing claims that animate the promotional materials have not been demonstrated in humans.
The honest patient framing:
- If you have specific clinical context (chronic fatigue, lingering symptoms after an acute illness, mild metabolic dysfunction), a clinician may consider prescribed injectable NAD+. Benefits are not established, and research is ongoing.
- If you are a healthy adult under 50 with no specific complaint, the evidence does not support strong recommendation. Diet, sleep, exercise, and stress management probably produce more measurable benefit per dollar.
- If you want to try oral precursors for general "longevity insurance," NR has the most-established evidence base. Expect modest, not dramatic, effects.
For how TelePep offers prescribed NAD+ and who it is for, see the NAD+ program page.
What patients should not do
Several patterns I have seen:
Substituting NAD+ for the basics. Sleep, exercise, dietary protein, stress management produce more measurable health effects than any NAD+ protocol. NAD+ is an adjunct, not a replacement.
Stacking everything. Some patients take oral NMN, oral NR, injectable NAD+, and a B-complex simultaneously. The additive benefit is unclear; the cost adds up. Pick one approach.
Believing the marketing. The longevity-supplement industry markets NAD+ precursors with claims that substantially exceed the evidence. The studies show modest effects; the marketing implies dramatic effects.
Buying research-grade NAD+ online. Unverified material with no clinical oversight. Use legitimate compounded NAD+ through a licensed pharmacy with a US-licensed prescriber.
TelePeptide's position
TelePeptide offers prescribed injectable NAD+ filled by licensed US compounding pharmacies, prescribed only if a licensed clinician finds it appropriate. The dose is set by the clinician and the pharmacy label. Research into NAD+ supplementation in people is ongoing and benefits are not established.
We do not sell oral NMN or NR; those are supplements, sold appropriately by supplement retailers, and do not require a clinical prescribing relationship.
The decision tree for patients evaluating NAD+ approaches:
- Do you have specific clinical context (fatigue, metabolic dysfunction)? Talk to a clinician about whether prescribed injectable NAD+ is worth considering.
- Are you healthy and curious about general longevity intervention? Oral NR is the most-evidenced option; expect modest effects; the basics (sleep, exercise, protein) likely produce more measurable benefit.
- Are you neither of the above? Save the money and focus on the fundamentals.
Bottom line
NAD+, NMN, and NR are different molecules with different routes, different bioavailability, different regulatory status, and different evidence bases. Oral NR has the most-established consumer-supplement evidence base. NMN is in regulatory limbo. For most healthy adults, the basics outpace any NAD+ protocol. For patients with specific clinical context, prescribed NAD+ may have a useful role. Match the intervention to your actual situation, not to the marketing.
Editorial note: TelePeptide (the company) is a US direct-pay telehealth brand. The brand name is sometimes autocorrected to "telopeptide": an unrelated collagen biomarker; the two terms have no clinical connection.
FAQ
Common questions
What is the difference between NAD+, NMN, and NR?
NAD+ is the active coenzyme. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors: molecules that the body converts into NAD+ through intracellular enzymes. NAD+ given by injection does not go through the conversion step oral precursors use; whether that changes outcomes has not been established. NMN and NR taken orally raise NAD+ through the precursor pathway and are easier to take.
Which is better: direct NAD+ injection or oral precursors?
Injected NAD+ does not go through the conversion step oral precursors use; whether that changes outcomes has not been established. Oral NMN and NR are easier and cheaper. Research is ongoing, and for most longevity-positioned uses the answer is unclear.
Is oral NMN or NR effective?
Both raise blood NAD+ levels modestly in humans. Both have been studied in small clinical trials with mixed results on functional endpoints. Neither has produced the dramatic longevity-marketing effects that promotional materials suggest. They are likely safe at studied doses; they may produce subtle benefits; the evidence does not support strong efficacy claims.
What is the regulatory status of NAD+, NMN, and NR?
NAD+ has a USP monograph and can be legitimately compounded by 503A pharmacies as an injectable. NMN was sold as a dietary supplement in the US until 2022, when FDA reclassified it as a drug (not a supplement) following an investigational new drug application. NR is sold as a dietary supplement under the brand name Niagen and similar formulations.
Are there safety concerns with these precursors?
At studied doses, all three appear well-tolerated in short-term human studies. Long-term safety (years to decades of administration) is not established for any of them. NAD+ injections occasionally produce facial flushing and brief chest tightness; oral NR and NMN are generally well-tolerated.
Should I take NAD+ if I am healthy?
The honest answer is uncertain. For a healthy adult under 50 with no specific clinical concern, the evidence base does not support a strong recommendation. For adults 50+ with subjective fatigue or mild metabolic dysfunction, a clinician may consider it, but benefits are not established. For specific clinical indications (chronic fatigue syndrome, post-COVID symptoms, neurodegenerative disease), targeted protocols are being studied, and nothing is established yet.
Next Step
Talk to a licensed clinician
A licensed clinician will review your goals and tell you whether a medication on the TelePep store is appropriate. No insurance, no waiting room.
Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.
TelePeptide offers direct-pay telehealth services. Independent licensed clinicians with Lone Star Virtual Health PLLC review every intake through the Bask Health platform and decide whether a prescription is appropriate. Prescriptions are filled by licensed US pharmacies; compounded medications are prepared by licensed US compounding pharmacies. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.